

RPG LIFE SCIENCES LIMITED Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071, India Tel: +91-22-25292152-55 Fax: +91-22-25297423

October 17, 2022

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C1, 'G' Block, Bandra-Kurla Complex Bandra (East), Mumbai 400 051. BSE Limited Corporate Relationship Department Floor 25, P.J. Towers Dalal Street Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sir/Madam,

Sub: Outcome of Board Meeting

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has, at its meeting held on Monday, October 17, 2022, inter-alia, considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2022. The said Unaudited Financial Results along with Limited Review Report of the Statutory Auditors thereon are enclosed herewith in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting commenced at 03:00 p.m. and concluded at 06:15 p.m.

Kindly take the above on record.

Thanking you,

Yours faithfully, For RPG Life Sciences Limited RAJESH RAMESH SHIRAMBEKAR Bajesh Shirambekar Head – Legal & Company Secretary





12th Floor, The Ruby 29 Senapati Bapat Marg Dadar (West) Mumbai - 400 028, India Tel :+91 22 6819 8000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors RPG Life Sciences Limited

- We have reviewed the accompanying statement of unaudited financial results of RPG Life Sciences Limited (the "Company") for the guarter ended September 30, 2022 and year to date from April 01, 2022, to September 30, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 5. The comparative Ind AS financial information of the Company for the corresponding quarter and period ended September 30, 2021, included in these Ind AS financial results, were reviewed by the predecessor auditor and the Ind AS financial statements of the Company for the year ended March 31, 2022, were audited by predecessor auditor who expressed an unmodified conclusion and unmodified opinion on those financial information on October 29, 2021 and April 29, 2022 respectively.

For S R B C & CO LLP Chartered Accountants ICAI Firm registration_aumber: 324982E/E300003

0 .

per Aruna Kumaraswamy Partner Membership No.: 219350 UDIN: 22219350AZZVNE9182 Place: Mumbai Date: October 17, 2022





RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127 Email: info@rpglifesciences.com www.rpglifesciences.com CIN: L24232MH2007PLC169354

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2022

-		Ouarter ended			Six months ended		(Rs. in Lakhs Year ended
	Particulars	30-09-2022	30-06-2022	30-09-2021	30-09-2022	30-09-2021	31-03-202
_		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	13,479	12,893	11,265	26,372	22,078	44,01
2		123	122	71	245	112	29
3	Total Income (1+2)	13,602	13,015	11,336	26,617	22,190	44,31
4							
	(a) Cost of Materials Consumed	2,218	2,126	1.899	4,344	3,986	8,81
	(b) Purchases of Stock-in-Trade	2,628	2,012	2,217	4,640	3,701	7,89
	(c) Changes in Inventories of Finished Goods, Work-in-				50		10.475
	Progress and Stock-in-Trade	(309)	216	(673)	(93)	(749)	(2,52
	(d) Employee Benefits Expense	2,792	2,708	2,577	5,500	4,937	9.99
	(e) Finance Costs	8	11	17	19	30	5
	(f) Depreciation and Amortisation Expense	387	383	399	770	795	1,56
	(g) Other Expenses	3,177	3,047	2,665	6,224	5,328	11,20
	Total Expenses	10,901	10,503	9,101	21,404	18,028	36,99
5	Profit before tax (3-4)	2,701	2,512	2,235	5,213	4,162	7,31
5	Income tax expenses						
	a. Current Tax	716	658	670	1,374	1,248	2,27
	b. Deferred Tax	(12)	33	(10)	21	(19)	(10
7	Profit for the period (5-6)	1,997	1,821	1,575	3,818	2,933	5,14
8	Other Comprehensive Income						
	 (i) Items that will not be reclassified to Profit or Loss (ii) Income tax relating to items that will not be reclassified 	(9)	(9)	(4)	(18)	(8)	(3
	to Profit or Loss	3	2	1	5	2	1
	Other Comprehensive Income Net of Tax	(6)	(7)	(3)	(13)	(6)	(2
Ì	Total Comprehensive Income for the period (7+8)	1,991	1,814	• 1,572	3,805	2,927	5,12
0	Paid-up Equity Share Capital	1,323	1,323	1,323	1,323	1,323	1,32
	(Face Value Rs. 8/- each)						
l	Other Equity	1					24,25
	Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):					24	
	(a) Basic (in Rs.)	12.08	11.01	9.52	23.09	17.74	31.1
	(b) Diluted (in Rs.)	12.08	11.01	9.52	23.09	17.74	31.1.

SIGNED FOR IDENTIFICATION BY 녑 SRBC&COLLP MUMBAI




PP J.19



RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127 Email: info@rpglifesciences.com www.rpglifesciences.com CIN : L24232MH2007PLC169354

Unaudited Balance Sheet as at September 30, 2022

	As at	(Rs. in Lakh As at	
Particulars	September 30, 2022	March 31, 2022	
	(Unaudited)	(Audited)	
ASSETS			
Non-current assets			
Property, plant and equipment (Including Right of use assets)	7,425	7,46	
Capital work-in-progress	2,845	2,54	
Other intangible assets	2,570	2,90	
Intangible assets under development	657	56	
Financial assets			
i. Loans	19	1	
ii. Other financial assets	44	3	
Current Tax asset (Net)	121	12	
Other non-current assets	214	11	
Total non-current assets	13,895	13,77	
Current assets	10,070	15,77	
Inventories	8,480	8,29	
Financial assets	0,400	0,29	
i. Investments	1,658	+	
i. Loans	2		
iii. Trade receivables	5,329	2.00	
		3,29	
iv. Cash and cash equivalents	5,087	5,69	
v. Bank balances other than (iii) above	1,342	1,33	
vi. Other financial assets	158	14	
Other current assets	1,480	1,91	
Total current assets	23,536	20,69	
Total assets	37,431	34,46	
EQUITY AND LIABILITIES			
Equity			
Equity share capital	1,323	1,32	
Other equity	26,471	24,25	
Total equity	27,794	25,57	
LIABILITIES			
Non-current liabilities			
Financial liabilities			
i. Borrowings	-		
ii. Lease liabilities	-	2	
iii. Other financial liabilities	302	31	
Provisions	304	30	
Deferred tax liabilities (Net)	242	22	
Total non-current liabilities	848	87	
Current liabilities			
Financial liabilities			
i. Borrowings	43	2	
ii. Lease liabilities	-	3	
iii. Trade payables			
(a) total outstanding dues of micro enterprises and small enterprises	634	34	
(b) total outstanding dues of creditors other than micro enterprises and			
small enterprises	4,900	4,20	
iv. Other financial liabilities	1,105	1,38	
Provisions	1,270	1,41	
Current tax liabilities (Net)	314	3	
Other current liabilities	523	550	
Total current liabilities	8,789	8,01	
Total liabilities	9,637	8,884	
Total equity and liabilities	37,431	34,46	





X

J.O 4

RPG LIFE SCIENCES


RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127 Email: info@rpglifesciences.com www.rpglifesciences.com

Unaudited statement of cash flows for the six months ended September 30, 2022

		(Rs. in Lakl		
	Particulars	For the period ended September 30, 2022	For the period ende September 30, 202	
	a a liculars			
	Cash Flow from operating activities	Unaudited	Unaudited	
	Profit before income tax	6.212		
	Adjustments for	5,213	4,162	
	Add:			
	Contract Contra			
	Depreciation and amortisation expenses	770	795	
	Finance costs	19	30	
	Unrealised exchange rate difference	(49)	(47	
	Provision for Doubtful Debts and Advances (Net)	21	8	
	Interest received	(141)	(30	
	Gain on sale of investments	(8)	(8	
	Net fair value gain on financial assets mandatorily measured at fair value through profit or loss	-	(53	
		5,825	4,857	
	Working capital adjustments:		1000000	
	(Increase) / Decrease in trade receivables	(1.000)		
	(Increase) / Decrease in financial assets - Loans	(1,989)	309	
		(9)	(2	
	(Increase) / Decrease in other non-current assets	-	6	
	(Increase) / Decrease in other financial assets	(22)	6	
	(Increase) / Decrease in other current assets	436	179	
	(Increase) / Decrease in inventories	(181)	(889	
	Increase / (Decrease) in trade payables	982	362	
	Increase / (Decrease) in other financial liabilities	(200)	(313	
	Increase / (Decrease) in provisions	(163)	10	
	Increase / (Decrease) in other current liabilities	(33)		
	Cash generated from operations	4,646	4,636	
	Income taxes paid	(1,097)	(727	
	Net cash inflow from operating activities	3,549	3,909	
1	Cash flow from investing activities:			
	Acquisition of property, plant and equipment and Intangible assets			
		(989)	(695)	
	Proceeds from sale of property, plant and equipment and Intangible assets Movement in Other bank balances (Net)	(H	-	
	Investment in Mutual Funds	(10)	(4,000)	
		(1,650)	-	
	Interest received	141	30	
	Net gain on sale of investments	-	8	
	Net cash (outflow) from investing activities	(2,508)	(4,657)	
l	Cash flow from financing activities			
	Proceeds from/ (Repayment of) long term borrowings	(5)	(6)	
	Proceeds from/ (Repayment of) Short-term Borrowings	19	(52)	
	Interest paid			
4	Repayment of principal portion of lease liability	(5)	(10)	
	Interest paid on lease liability	(65)	(35)	
	Dividend paid	(4)	. (9)	
ъ		(1,588)	(1,191)	
	Net cash (outflow) from financing activities	(1,648)	(1,303)	
1	Net (decrease)/increase in cash and cash equivalents	(607)	(2,051)	
	Add: Cash and cash equivalents at the beginning of the financial period	5,694	4,036	

Notes:

- The above Unaudited Financial Results have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meetings held on October 17, 2022.
- 2. The Company operates in only one reportable business segment i.e. Pharmaceuticals.
- During the quarter ended 30th June 2022, the Company exercised the option of lower tax rate under section 115 BAA of Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Act, 2019 effective April 01, 2022. Accordingly, the Company has adopted the new tax rate of 25.17% which has resulted in a reversal of deferred tax balances of Rs 46 lakhs on account of remeasurement of deferred tax balances as at 31st March, 2022 and is recognised in the financial results for the quarter ended 30th June, 2022
- 4. Previous period's figures have been regrouped/reclassified wherever necessary.





For RPG Life Sciences Limited

10 uc

Yugal Sikri Managing Director Mumbai, October 17, 2022 An SRPG Company